Reimbursed Care Access in Sint Maarten (Dutch part)
In Sint Maarten (Dutch part) there is no established, reimbursed medical framework for classical psychedelic medicines. Most tryptamines, phenethylamines and other classic psychedelics are treated under national narcotics/psychotropic drug controls and have no authorized medical reimbursement pathway; ketamine is used as an anesthetic in clinical settings but there is no publicly documented, reimbursed psychedelic-psychiatric program or national coverage for psychedelic-assisted therapies.
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
MDMA
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Esketamine
No publicly documented national reimbursement program or routine clinical availability of esketamine (Spravato) for psychiatric use in Sint Maarten. There is no evidence of a national, government-funded reimbursement pathway for esketamine; access, if available, would be limited to participating clinical research sites or private importation under special authorization. Currently classified and handled under controlled-medicine / importation regulation frameworks in the territory with no established public-coverage policy.
Ketamine
Ketamine is used and available in Sint Maarten for standard medical indications such as anesthesia and acute medical/surgical care; this reflects routine hospital practice rather than a reimbursed, standardized psychedelic-assisted psychotherapy program. Use of ketamine for psychiatric indications (e.g., off-label infusions for depression) would be off-label, arranged through private providers/hospitals and is not known to be covered by a territory-wide public reimbursement program. Clinical use for anesthesia and emergency medicine follows medical supply/import regulation rather than any psychedelics-specific reimbursement policy.
DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
5-MeO-DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Ibogaine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Ayahuasca
Currently classified as a strictly controlled substance (because DMT is a controlled constituent), with no authorized medical use outside of approved clinical research or specially authorized ceremonial exceptions; there is no public reimbursement or regulated therapeutic program documented.
Mescaline
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
2C-X
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.